全文获取类型
收费全文 | 1288021篇 |
免费 | 95640篇 |
国内免费 | 1991篇 |
专业分类
耳鼻咽喉 | 18409篇 |
儿科学 | 42770篇 |
妇产科学 | 38233篇 |
基础医学 | 188812篇 |
口腔科学 | 35630篇 |
临床医学 | 109693篇 |
内科学 | 253470篇 |
皮肤病学 | 26638篇 |
神经病学 | 100303篇 |
特种医学 | 50590篇 |
外国民族医学 | 369篇 |
外科学 | 199248篇 |
综合类 | 26880篇 |
现状与发展 | 1篇 |
一般理论 | 324篇 |
预防医学 | 94045篇 |
眼科学 | 29196篇 |
药学 | 98966篇 |
2篇 | |
中国医学 | 2498篇 |
肿瘤学 | 69575篇 |
出版年
2018年 | 12053篇 |
2016年 | 10265篇 |
2015年 | 11854篇 |
2014年 | 16348篇 |
2013年 | 24879篇 |
2012年 | 34284篇 |
2011年 | 36753篇 |
2010年 | 21629篇 |
2009年 | 20378篇 |
2008年 | 35598篇 |
2007年 | 38615篇 |
2006年 | 39180篇 |
2005年 | 38480篇 |
2004年 | 37010篇 |
2003年 | 35926篇 |
2002年 | 35462篇 |
2001年 | 58545篇 |
2000年 | 60053篇 |
1999年 | 51085篇 |
1998年 | 14433篇 |
1997年 | 12970篇 |
1996年 | 13248篇 |
1995年 | 12528篇 |
1994年 | 11911篇 |
1993年 | 11000篇 |
1992年 | 41310篇 |
1991年 | 40726篇 |
1990年 | 40208篇 |
1989年 | 39015篇 |
1988年 | 36362篇 |
1987年 | 35620篇 |
1986年 | 34006篇 |
1985年 | 32435篇 |
1984年 | 24123篇 |
1983年 | 20985篇 |
1982年 | 12474篇 |
1981年 | 10998篇 |
1979年 | 22830篇 |
1978年 | 16003篇 |
1977年 | 13837篇 |
1976年 | 13046篇 |
1975年 | 14290篇 |
1974年 | 16794篇 |
1973年 | 16193篇 |
1972年 | 15438篇 |
1971年 | 14346篇 |
1970年 | 13324篇 |
1969年 | 12823篇 |
1968年 | 12066篇 |
1967年 | 10547篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
31.
32.
33.
34.
Dermoscopic difficult lesions: an objective evaluation of reflectance confocal microscopy impact for accurate diagnosis 下载免费PDF全文
35.
D. Baker G. Pryce L. K. James K. Schmierer G. Giovannoni 《European journal of neurology》2020,27(2):221-228
Clinical trials are probably the most informative experiments to help an understanding of multiple sclerosis (MS) biology. Recent successes with CD20‐depleting antibodies have focused attention towards B cell subsets as important mediators in MS. The trial of tabalumab (NTC00882999), which inhibits B cell activation factor (BAFF), is reported and reviewed and this trial is contrasted with the trial on the inhibition of a proliferation‐inducing ligand (APRIL) and BAFF using atacicept (NCT00642902). Both tabalumab and atacicept induce depletion of mature B cells and inhibit antibody formation, but they fail to deplete memory B cells and do not inhibit relapsing MS. Atacicept is reported to augment memory B cell responses and may precipitate relapse, suggesting the importance of APRIL. However, BAFF inhibition can enhance peripheral blood memory B cell responses, which was not associated with augmented relapse. Although other interpretations are possible, these data further support the hypothesis that memory B cells may be of central importance in relapsing MS, as they are the major CD20+ B cell subset expressing APRIL receptors. They also suggest that quantitative and/or qualitative differences in B cell responses or other factors, such as an immune‐regulatory effect associated with APRIL, may be important in determining whether MS reactivates following neutralization of peripheral B cell maturation and survival factors. 相似文献
36.
37.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
38.
39.